vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and UNIVEST FINANCIAL Corp (UVSP). Click either name above to swap in a different company.
UNIVEST FINANCIAL Corp is the larger business by last-quarter revenue ($87.5M vs $47.7M, roughly 1.8× IRONWOOD PHARMACEUTICALS INC). UNIVEST FINANCIAL Corp runs the higher net margin — 31.0% vs -4.8%, a 35.7% gap on every dollar of revenue. Over the past eight quarters, UNIVEST FINANCIAL Corp's revenue compounded faster (10.2% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Univest Financial Corp is a U.S. regional financial services holding company based in Pennsylvania. It offers banking, wealth management, insurance, and lending solutions for individual consumers, SMEs, and institutional clients across its Mid-Atlantic operating regions.
IRWD vs UVSP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $87.5M |
| Net Profit | $-2.3M | $27.1M |
| Gross Margin | — | — |
| Operating Margin | 14.3% | — |
| Net Margin | -4.8% | 31.0% |
| Revenue YoY | -47.3% | — |
| Net Profit YoY | -200.9% | — |
| EPS (diluted) | $0.01 | $0.96 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $87.5M | ||
| Q4 25 | $47.7M | $84.6M | ||
| Q3 25 | $122.1M | $83.2M | ||
| Q2 25 | $85.2M | $81.0M | ||
| Q1 25 | $41.1M | $79.2M | ||
| Q4 24 | $90.5M | $76.8M | ||
| Q3 24 | $91.6M | $73.4M | ||
| Q2 24 | $94.4M | $72.0M |
| Q1 26 | — | $27.1M | ||
| Q4 25 | $-2.3M | $22.7M | ||
| Q3 25 | $40.1M | $25.6M | ||
| Q2 25 | $23.6M | $20.0M | ||
| Q1 25 | $-37.4M | $22.4M | ||
| Q4 24 | $2.3M | $18.9M | ||
| Q3 24 | $3.6M | $18.6M | ||
| Q2 24 | $-860.0K | $18.1M |
| Q1 26 | — | — | ||
| Q4 25 | 14.3% | 34.0% | ||
| Q3 25 | 61.8% | 38.5% | ||
| Q2 25 | 53.2% | 30.9% | ||
| Q1 25 | -70.7% | 34.8% | ||
| Q4 24 | 34.8% | 30.9% | ||
| Q3 24 | 28.0% | 31.9% | ||
| Q2 24 | 26.5% | 31.4% |
| Q1 26 | — | 31.0% | ||
| Q4 25 | -4.8% | 26.9% | ||
| Q3 25 | 32.8% | 30.8% | ||
| Q2 25 | 27.7% | 24.7% | ||
| Q1 25 | -90.9% | 28.3% | ||
| Q4 24 | 2.5% | 24.7% | ||
| Q3 24 | 4.0% | 25.3% | ||
| Q2 24 | -0.9% | 25.1% |
| Q1 26 | — | $0.96 | ||
| Q4 25 | $0.01 | $0.78 | ||
| Q3 25 | $0.23 | $0.89 | ||
| Q2 25 | $0.14 | $0.69 | ||
| Q1 25 | $-0.23 | $0.77 | ||
| Q4 24 | $0.03 | $0.64 | ||
| Q3 24 | $0.02 | $0.63 | ||
| Q2 24 | $-0.01 | $0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $222.4M |
| Total DebtLower is stronger | — | $201.2M |
| Stockholders' EquityBook value | $-261.8M | $952.0M |
| Total Assets | $396.9M | $8.1B |
| Debt / EquityLower = less leverage | — | 0.21× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $222.4M | ||
| Q4 25 | $215.5M | — | ||
| Q3 25 | $140.4M | — | ||
| Q2 25 | $92.9M | — | ||
| Q1 25 | $108.5M | — | ||
| Q4 24 | $88.6M | — | ||
| Q3 24 | $88.2M | — | ||
| Q2 24 | $105.5M | — |
| Q1 26 | — | $201.2M | ||
| Q4 25 | — | — | ||
| Q3 25 | $199.5M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $199.2M | — | ||
| Q4 24 | $199.0M | — | ||
| Q3 24 | $198.8M | — | ||
| Q2 24 | $198.6M | — |
| Q1 26 | — | $952.0M | ||
| Q4 25 | $-261.8M | $943.3M | ||
| Q3 25 | $-264.2M | $933.2M | ||
| Q2 25 | $-308.2M | $916.7M | ||
| Q1 25 | $-334.1M | $903.5M | ||
| Q4 24 | $-301.3M | $887.3M | ||
| Q3 24 | $-311.3M | $877.1M | ||
| Q2 24 | $-321.7M | $854.1M |
| Q1 26 | — | $8.1B | ||
| Q4 25 | $396.9M | $8.4B | ||
| Q3 25 | $396.1M | $8.6B | ||
| Q2 25 | $342.9M | $7.9B | ||
| Q1 25 | $327.2M | $8.0B | ||
| Q4 24 | $350.9M | $8.1B | ||
| Q3 24 | $389.5M | $8.2B | ||
| Q2 24 | $395.6M | $7.9B |
| Q1 26 | — | 0.21× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | — |
| Free Cash FlowOCF − Capex | $74.6M | — |
| FCF MarginFCF / Revenue | 156.3% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $74.6M | $101.5M | ||
| Q3 25 | $47.6M | $32.0M | ||
| Q2 25 | $-15.1M | $23.3M | ||
| Q1 25 | $20.0M | $15.6M | ||
| Q4 24 | $15.2M | $75.1M | ||
| Q3 24 | $9.9M | $38.9M | ||
| Q2 24 | $33.5M | $-3.4M |
| Q1 26 | — | — | ||
| Q4 25 | $74.6M | $96.9M | ||
| Q3 25 | $47.6M | $31.4M | ||
| Q2 25 | $-15.1M | $21.9M | ||
| Q1 25 | $19.9M | $13.7M | ||
| Q4 24 | — | $72.0M | ||
| Q3 24 | $9.9M | $38.3M | ||
| Q2 24 | $33.4M | $-4.2M |
| Q1 26 | — | — | ||
| Q4 25 | 156.3% | 114.6% | ||
| Q3 25 | 39.0% | 37.7% | ||
| Q2 25 | -17.7% | 27.0% | ||
| Q1 25 | 48.4% | 17.2% | ||
| Q4 24 | — | 93.8% | ||
| Q3 24 | 10.8% | 52.2% | ||
| Q2 24 | 35.4% | -5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.4% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.1% | 2.5% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.1% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.46× | ||
| Q3 25 | 1.19× | 1.25× | ||
| Q2 25 | -0.64× | 1.16× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | 6.74× | 3.97× | ||
| Q3 24 | 2.71× | 2.09× | ||
| Q2 24 | — | -0.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRWD
Segment breakdown not available.
UVSP
| Net Interest Income | $63.4M | 72% |
| Noninterest Income | $24.1M | 28% |
